12 drug(s) with this reaction
7,952 total reports
Chronic Kidney Disease has been reported as an adverse reaction across 12 drug(s) manufactured by Haleon Us Holdings Llc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 7,952 adverse event reports mention chronic kidney disease in connection with Haleon Us Holdings Llc products.
This page provides a breakdown of which Haleon Us Holdings Llc drugs are most commonly associated with chronic kidney disease, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Haleon Us Holdings Llc drugs have chronic kidney disease listed in their FDA adverse event reports, sorted by report count:
In addition to chronic kidney disease, the following adverse reactions have been reported across Haleon Us Holdings Llc's drug portfolio:
12 drug(s) manufactured by Haleon Us Holdings Llc have chronic kidney disease listed in their FDA adverse event reports: CALCIUM CARBONATE, FLUTICASONE PROPIONATE, ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE HCL, ALUMINUM HYDROXIDE AND MAGNESIUM CARBONATE, NICOTINE, and others.
There are a combined 7,952 reports of chronic kidney disease across 12 Haleon Us Holdings Llc drug(s) in the FDA adverse event database.